Pharmaceutical Pfizer acknowledged this Friday (17) that its double-dose vaccine against Covid-19 has not been shown to be effective in studies with children aged 2 to 5 years and said it will now try to add a third application to increase this effectiveness .
The third dose of at least three micrograms will be administered two months after the second vaccine “to provide high levels of protection in this age group,” the US company said in an official statement.
read more :
If the study shows greater effectiveness with this third injection, Pfizer will present the formulation to regulatory agencies in the first half of 2022 for approval of an emergency use permit.
Studies in children have shown, however, that the double dose was adequate for infants 6 to 24 months of age. In addition, the company says it will consider whether to recommend a third dose of 10 micrograms for people aged between 5 and 12 years.
Source: Full News
